Rapid progress at Open Orphan #ORPH. In Pfizer’s recent quarterly update, CEO Albert Bourla, noted (on page 5) that one of the key highlights of Pfizer’s Q2 was the “Successful Phase 2a human challenge trial with RSV Adult vaccine candidate”.
Although Pfizer have not mentioned Open Orphan by name and we have not formally announced our involvement, hVIVO is listed as the sponsor to the study here and with hVIVO contact details noted on the Pfizer website here:
